Are There Therapeutic Strategies Targeting Alternative Splicing in Cancer?
Targeting alternative splicing represents a promising therapeutic strategy in cancer treatment. Small molecules, antisense oligonucleotides (ASOs), and splice-switching oligonucleotides (SSOs) are being developed to modulate splicing events. These approaches aim to correct aberrant splicing patterns or to induce the skipping of exons that produce oncogenic protein isoforms. For example, E7107, a small molecule inhibitor of the spliceosome, has shown potential in preclinical studies for treating cancers with splicing factor mutations.
